

Supporting Information

Docking and in vitro molecular biology studies of p-anisidine appended 1-hydroxy-2-acetonaphthanone Schiff base Lanthanum(III) complexes

Content

- Figure S1** ^1H NMR spectrum of ligand 3 in CDCl_3 at 25°C
- Figure S2** ^{13}C -NMR spectrum of ligand 3 in CDCl_3 at 25°C
- Figure S3** ESI mass spectrum of ligand 3
- Figure S4** ESI mass spectrum of complex 4
- Figure S5** ESI mass spectrum of complex 5
- Figure S6** ESI mass spectrum of complex 6
- Figure S7** FTIR spectral comparison of 3, 4, 5, and 6
- Figure S8** Electronic absorption spectra of 3, 4, 5 and 6 in methanol
- Figure S9** Emission spectra of 3, 4, 5 and 6 in ethanol excited at λ_{ex} 300 nm
- Figure S10** Concentration versus viability plot of incubated HeLa cells with varying concentrations of the ligand and complexes.
- Figure S11** DPPH free radical scavenging activity of 3, 4, 5, and 6
- Figure S12** Concentration versus viability plot of incubated HeLa cells with varying concentrations of the ligand and complexes.
- Figure S13** Histogram showing percent distribution of cells in G2, S and G1.
- Figure S14** Carcinogenicity/Cytotoxicity/Mutagenicity Screening

| | |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Figure S15 | Representative image for chromosomal aberration of (a) 5 treated with cell line with normal metaphase (b) Mitomycin treated cells with metaphase aberration exchange |
| Table S1 | LCMS-MS-Mass spectrometry optimized selected parameters for the compounds |
| Table S2 | Intercalation of L1HSm with DNA (PDB ID: 1BNA; Q-Site Finder) and Preferential Binding Site from the Docked Structure |
| Table S3 | Molecular Docking Data of HSA (PDB ID: 1h9z; Q-Site Finder) and Preferential Binding Site of L1HSm(5) from Docked Structure |
| Table S4 | Chromosome aberration test in cultured CHO-K1 cells with different concentrations of L1HSm (5). |

Figure S1. ^1H NMR spectrum of ligand 3 in CDCl_3 at 25°C .




Figure S2. ^{13}C -NMR spectrum of ligand 3 in CDCl_3 at 25°C .




Figure S3. (a) ESI direct mass spectrum, (b) LC-MS chromatogram, and (c) total ion MS spectrum of LCMS for ligand 3.




Figure S4. (a) ESI direct mass spectrum, (b) LC-MS chromatogram, and (c) total ion MS spectrum of LCMS for complex 4.




Figure S5. ESI direct mass spectrum, (b) LC-MS chromatogram, and (c) total ion MS spectrum of LCMS for complex 5.




Figure S6 ESI direct mass spectrum, (b) LC-MS chromatogram, and (c) total ion MS spectrum of LCMS for complex 6.




Figure S7 FTIR spectral comparison of 3, 4, 5, and 6.




Figure S8 Electronic absorption spectra of 3, 4, 5, and 6 in methanol.




Figure S9. Emission spectra of 3, 4, 5, and 6 in ethanol excited at λ_{ex} 300 nm.




Figure S10. Concentration versus viability plot of incubated HeLa cells with varying concentrations of the ligand and complexes.




Figure S11. DPPH free radical scavenging activity of 3, 4, 5, and 6.




Figure S12. Concentration versus viability plot of incubated HeLa cells with varying concentrations of the ligand and complexes. (a) 3D bar diagram of cell viability of ligand and complexes. (b) Regression plot for the estimation of IC_{50} values from the test concentrations.




Figure S13. Histogram showing the percent distribution of cells in G2, S, and G1.




Figure S14. Carcinogenicity/cytotoxicity/mutagenicity screening (a) positive control-stannous chloride at various levels (2, 1, 0.5, 0.25, 0.125 mg) tested, (b) representative sample 6 at various levels (2, 1, 0.5, 0.25, 0.125 mg) tested, and (c) graphical representation of the concentration vs zone of inhibition.




Figure S15. Representative image for chromosomal aberration of (a) complex 5 treated with cell line with normal metaphase, (b) Mitomycin treated cells with metaphase aberration exchange.

Table: S1 LCMS-MS-Mass spectrometry optimized selected parameters for the compounds.

| Compound | Retention time (t _R) | Precursor ion (m/z) | CE (V) | Product ion (m/z) | CE (V) | Tube Lens |
|----------|----------------------------------|---------------------|--------|--------------------------------------------------------------------------------------------|--------|-----------|
| 4 | 5.81 min | 885.29 | 11 | 865.14, 866.16, 867.15 and 868.16 | 22 | 72 |
| 5 | 8.31 min | 895.19 | 15 | 850.14, 851.15, 853.14, 855.16, 856.16, 857.15, 858.15, 859.15, 860.14, 861.15 and 862.15. | 19 | 74 |
| 6 | 5.75 min | 917.36 | 18 | 894.17, 895.16, 896.16, 897.14, 898.15, 899.15, 900.16 and 901.14 | 18 | 76 |

Table S2. Intercalation of LIHSm with DNA (PDB ID: 1BNA; Q-site finder) and preferential binding site from the docked structure.

| B-DNA DODECAMER | | | LIHSm | Geometric Shape Complementarity Score | DISTANCE Å | H-BOND |
|--------------------|---|-----|-------|------------------------------------------|---------------|--------|
| DA 18 | B | O4' | C | 5136 | — | — |
| DC 9 | A | O2 | C | | | |

The -DNA DODECAMER,

1. Atom of DA position 18 O4' is bond to ligand of atom C.

| | | | | | | | | | | | |
|-----|------|-----|-----|------|----|--------|--------|-------|------|-------|---|
| 734 | ATOM | 343 | N3 | DA B | 17 | 15.700 | 22.472 | 2.783 | 1.00 | 38.96 | N |
| 735 | ATOM | 344 | C4 | DA B | 17 | 16.791 | 21.706 | 3.002 | 1.00 | 28.24 | C |
| 736 | ATOM | 345 | P | DA B | 18 | 19.803 | 27.141 | 2.526 | 1.00 | 46.11 | P |
| 737 | ATOM | 346 | OP1 | DA B | 18 | 19.796 | 28.478 | 1.888 | 1.00 | 49.20 | O |
| 738 | ATOM | 347 | OP2 | DA B | 18 | 20.953 | 26.858 | 3.426 | 1.00 | 43.48 | O |
| 739 | ATOM | 348 | O5' | DA B | 18 | 18.396 | 26.939 | 3.241 | 1.00 | 40.83 | O |
| 740 | ATOM | 349 | C5' | DA B | 18 | 17.203 | 27.028 | 2.452 | 1.00 | 40.72 | C |
| 741 | ATOM | 350 | C4' | DA B | 18 | 16.035 | 26.958 | 3.388 | 1.00 | 66.52 | C |
| 742 | ATOM | 351 | O4' | DA B | 18 | 15.856 | 25.612 | 3.850 | 1.00 | 44.25 | O |
| 743 | ATOM | 352 | C3' | DA B | 18 | 16.101 | 27.861 | 4.615 | 1.00 | 63.34 | C |
| 744 | ATOM | 353 | O3' | DA B | 18 | 14.890 | 28.608 | 4.757 | 1.00 | 55.65 | O |
| 745 | ATOM | 354 | C2' | DA B | 18 | 16.368 | 26.844 | 5.724 | 1.00 | 34.49 | C |
| 746 | ATOM | 355 | C1' | DA B | 18 | 15.561 | 25.655 | 5.243 | 1.00 | 29.45 | C |
| 747 | ATOM | 356 | N9 | DA B | 18 | 16.104 | 24.373 | 5.755 | 1.00 | 20.03 | N |
| 748 | ATOM | 357 | C8 | DA B | 18 | 17.411 | 23.967 | 5.830 | 1.00 | 16.51 | C |
| 749 | ATOM | 358 | N7 | DA B | 18 | 17.539 | 22.706 | 6.276 | 1.00 | 20.58 | N |
| 750 | ATOM | 359 | C5 | DA B | 18 | 16.266 | 22.309 | 6.480 | 1.00 | 21.66 | C |

2. Atom of DC position 9 O2 is bond to ligand of atom C.

| | | | | | | | | | | | | |
|-----|------|-----|-----|----|---|---|--------|--------|-------|------|-------|---|
| 552 | ATOM | 161 | C6 | DT | A | 8 | 10.201 | 18.110 | 1.000 | 1.00 | 21.00 | C |
| 553 | ATOM | 162 | P | DC | A | 9 | 5.531 | 23.071 | 3.209 | 1.00 | 48.97 | P |
| 554 | ATOM | 163 | OP1 | DC | A | 9 | 4.648 | 24.244 | 3.269 | 1.00 | 62.33 | O |
| 555 | ATOM | 164 | OP2 | DC | A | 9 | 5.010 | 21.905 | 2.470 | 1.00 | 51.53 | O |
| 556 | ATOM | 165 | O5' | DC | A | 9 | 6.926 | 23.547 | 2.611 | 1.00 | 43.99 | O |
| 557 | ATOM | 166 | C5' | DC | A | 9 | 7.636 | 24.627 | 3.249 | 1.00 | 50.86 | C |
| 558 | ATOM | 167 | C4' | DC | A | 9 | 8.897 | 24.853 | 2.457 | 1.00 | 46.66 | C |
| 559 | ATOM | 168 | O4' | DC | A | 9 | 9.638 | 23.627 | 2.448 | 1.00 | 42.69 | O |
| 560 | ATOM | 169 | C3' | DC | A | 9 | 8.717 | 25.240 | 0.998 | 1.00 | 56.96 | C |
| 561 | ATOM | 170 | O3' | DC | A | 9 | 9.470 | 26.414 | 0.667 | 1.00 | 63.54 | O |
| 562 | ATOM | 171 | C2' | DC | A | 9 | 9.126 | 23.965 | 0.253 | 1.00 | 50.41 | C |
| 563 | ATOM | 172 | C1' | DC | A | 9 | 10.241 | 23.483 | 1.157 | 1.00 | 41.08 | C |
| 564 | ATOM | 173 | N1 | DC | A | 9 | 10.524 | 22.022 | 1.015 | 1.00 | 37.23 | N |
| 565 | ATOM | 174 | C2 | DC | A | 9 | 11.814 | 21.603 | 0.840 | 1.00 | 40.54 | C |
| 566 | ATOM | 175 | O2 | DC | A | 9 | 12.691 | 22.447 | 0.670 | 1.00 | 43.89 | O |
| 567 | ATOM | 176 | N3 | DC | A | 9 | 12.106 | 20.297 | 0.873 | 1.00 | 32.57 | N |
| 568 | ATOM | 177 | C4 | DC | A | 9 | 11.141 | 19.395 | 1.046 | 1.00 | 24.65 | C |
| 569 | ATOM | 178 | N4 | DC | A | 9 | 11.461 | 18.075 | 1.089 | 1.00 | 27.84 | N |

Table S3. Molecular docking data of HSA (PDB ID: 1h9z; Q-site finder) and preferential binding site of L1HSm(5) from the docked structure.

| Serum | Ligand | Geometrical shape | Distance Å | H-Bond |
|---------|--------|---------------------|------------|--------|
| Albumin | | complementary score | | |
| TRY | OH | O | 5492 | 3.07 |
| 150 | | | | 4 |
| TRY | OH | O | | 3.23 |
| 150 | | | | |
| TRY | OH | O | | 2.68 |
| 150 | | | | |
| TRY | OH | N | | 2.94 |
| 150 | | | | |

The protein Serum Albumin,

1. Amino acid Tyrosine of position 150 of atom OH is bond to ligand of atom O.
2. Amino acid Tyrosine of position 150 of atom OH is bond to ligand of atom O.
3. Amino acid Tyrosine of position 150 of atom OH is bond to ligand of atom O.
4. Amino acid Tyrosine of position 150 of atom OH is bond to ligand of atom N.

Table: S4 Chromosome aberration test in cultured CHO-K1 cells with different concentrations of L1HSm (5).

| Concentration (mg/mL) | Treatment duration (h) | No. of Aberrant cells | No. of non Aberrant cells | <i>P</i> value | |
|---------------------------------------------|---------------------------|-----------------------------|---------------------------------|----------------|--------|
| | | | | 4 h | 21 h |
| Negative control (0.0) | 4 | 2 | 298 | 0.546 | 0.881 |
| | 21 | 3 | 297 | | |
| 1.25 | 4 | 2 | 298 | | |
| | 21 | 1 | 299 | | |
| 2.5 | 4 | 1 | 299 | | |
| | 21 | 3 | 297 | | |
| 5.0 | 4 | 4 | 296 | | |
| | 21 | 2 | 298 | | |
| Positive control (0.3 µg Mitomycin C) | 4 | 16 | 284 | 0.001* | 0.001* |
| | 21 | 18 | 282 | | |

* Significant